Nona Biosciences, a global biotechnology company providing a total solution from “Idea to IND,” ranging from target validation and antibody discovery through preclinical research, has entered into a license agreement with AstraZeneca for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology.   Under the terms of the agreement, Nona Biosciences will receive $19 million upon completion of the transaction. Nona is eligible to receive an additional $10 ...